{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:11:37Z","timestamp":1793232697947,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.vaccine.2021.01.066","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T02:35:18Z","timestamp":1613874918000},"page":"1556-1564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries"],"prefix":"10.1016","volume":"39","author":[{"given":"Molly","family":"Sauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1016-5998","authenticated-orcid":false,"given":"Prarthana","family":"Vasudevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4952-6017","authenticated-orcid":false,"given":"Ankita","family":"Meghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karuna","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Deloria","family":"Knoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Privor-Dumm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.01.066_b0005","unstructured":"United Nations Department of Economic and Social Affairs, Population Division. World Population Prospects 2019: Highlights. 2019."},{"issue":"9967","key":"10.1016\/j.vaccine.2021.01.066_b0010","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(14)61462-8","article-title":"Health, functioning, and disability in older adults\u2013present status and future implications","volume":"385","author":"Chatterji","year":"2015","journal-title":"Lancet"},{"issue":"9963","key":"10.1016\/j.vaccine.2021.01.066_b0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"GBD Mortality Causes of Death Collaborators","year":"2015","journal-title":"Lancet"},{"issue":"4 Suppl","key":"10.1016\/j.vaccine.2021.01.066_b0020","first-page":"S1","article-title":"Update on vaccine-preventable diseases: are adults in your community adequately protected?","volume":"57","author":"Schaffner","year":"2008","journal-title":"J Fam Pract."},{"key":"10.1016\/j.vaccine.2021.01.066_b0025","unstructured":"Chen W. Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly. WHO meeting on Immunization of the Elderly2017."},{"key":"10.1016\/j.vaccine.2021.01.066_b0030","unstructured":"U.S. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States 2019. Atlanta: U.S. Department of Health and Human Services 2019."},{"key":"10.1016\/j.vaccine.2021.01.066_b0035","unstructured":"World Health Organization. Global Vaccine Action Plan, 2011-2020. 2013."},{"key":"10.1016\/j.vaccine.2021.01.066_b0040","unstructured":"World Health Organization. Strengthening immunization to achieve the goals of the global vaccine action plan. Seventieth World Health Assembly; 2017."},{"key":"10.1016\/j.vaccine.2021.01.066_b0045","unstructured":"World Health Organization. Multisectoral action for a life course approach to healthy ageing. 2013."},{"issue":"9595","key":"10.1016\/j.vaccine.2021.01.066_b0050","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S0140-6736(07)61579-7","article-title":"Generation of political priority for global health initiatives: a framework and case study of maternal mortality","volume":"370","author":"Shiffman","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.01.066_b0055","doi-asserted-by":"crossref","unstructured":"Privor-Dumm L, Sandiford D, P V, Portnoy A, Spencer D, Stanway J. A Global Effort for Adult Vaccines: Potential Roadmap for Access. 10th International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD-10); Glasgow, Scotland; 2016.","DOI":"10.26226\/morressier.5731f0d6d462b8029237fc3e"},{"key":"10.1016\/j.vaccine.2021.01.066_b0060","unstructured":"Adult vaccination: a key component of healthy aging. The Supporting Active Ageing Through Immunisation (SAATI) Partnership; 2013."},{"key":"10.1016\/j.vaccine.2021.01.066_b0065","unstructured":"Cost-effectiveness of adult immunization strategies: Report. Heron; 2013."},{"issue":"12","key":"10.1016\/j.vaccine.2021.01.066_b0070","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost-effectiveness thresholds: pros and cons","volume":"94","author":"Bertram","year":"2016","journal-title":"Bull World Health Organ."},{"issue":"46","key":"10.1016\/j.vaccine.2021.01.066_b0075","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1016\/j.vaccine.2013.09.013","article-title":"Influenza cost and cost-effectiveness studies globally\u2013a review","volume":"31","author":"Peasah","year":"2013","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.01.066_b0080","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2016 (GBD 2016) Cause-Specific Mortality 1980-2016. Institute for Health Metrics and Evaluation, editor. Seattle, United States 2017."},{"issue":"10033","key":"10.1016\/j.vaccine.2021.01.066_b0085","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/S0140-6736(15)00516-4","article-title":"The World report on ageing and health: a policy framework for healthy ageing","volume":"387","author":"Beard","year":"2016","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2021.01.066_b0090","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1093\/geront\/gnw037","article-title":"The world report on ageing and health","volume":"56","author":"Beard","year":"2016","journal-title":"Gerontologist."},{"issue":"12","key":"10.1016\/j.vaccine.2021.01.066_b0095","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/gerona\/gly011","article-title":"Evidence for the domains supporting the construct of intrinsic capacity","volume":"73","author":"Cesari","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.066_b0100","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2567.2007.02555.x","article-title":"Immunosenescence: emerging challenges for an ageing population","volume":"120","author":"Aw","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2021.01.066_b0105","unstructured":"World Health Organization. World Report on Ageing and Health. 2015."},{"issue":"7","key":"10.1016\/j.vaccine.2021.01.066_b0110","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.vaccine.2017.12.029","article-title":"Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22\u201323 March 2017","volume":"36","author":"Teresa Aguado","year":"2018","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.01.066_b0115","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Cause-Specific Mortality 1980-2017. Institute for Health Metrics and Evaluation, editor. Seattle, United States, 2018."},{"key":"10.1016\/j.vaccine.2021.01.066_b0120","unstructured":"World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2017 global summary 2017 [Available from: http:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/schedules."},{"issue":"9967","key":"10.1016\/j.vaccine.2021.01.066_b0125","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(14)61347-7","article-title":"The burden of disease in older people and implications for health policy and practice","volume":"385","author":"Prince","year":"2015","journal-title":"Lancet"},{"issue":"10053","key":"10.1016\/j.vaccine.2021.01.066_b0130","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the global burden of disease study 2015","volume":"388","author":"Global Burden of Disease Collaborative Network","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.066_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170412","article-title":"Burden of pneumococcal disease in northern togo before the introduction of pneumococcal conjugate vaccine","volume":"12","author":"Moisi","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.vaccine.2021.01.066_b0140","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1186\/s12889-015-1753-y","article-title":"Herpes zoster-associated mortality in Europe: a systematic review","volume":"15","author":"Bricout","year":"2015","journal-title":"BMC Public Health."},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.066_b0145","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s15010-015-0789-3","article-title":"Clinical and economic burden of community-acquired pneumonia in the Veterans Health Administration, 2011: a retrospective cohort study","volume":"43","author":"McLaughlin","year":"2015","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2021.01.066_b0150","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12879-015-1004-y","article-title":"Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection-United States, 2005\u20132008","volume":"15","author":"Garg","year":"2015","journal-title":"BMC Infect Dis."},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.066_b0155","doi-asserted-by":"crossref","first-page":"E545","DOI":"10.9778\/cmajo.20160035","article-title":"The epidemiology of invasive pneumococcal disease in older adults from 2007 to 2014 in Ontario, Canada: a population-based study","volume":"4","author":"Desai","year":"2016","journal-title":"CMAJ Open."},{"key":"10.1016\/j.vaccine.2021.01.066_b0160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41479-016-0008-8","article-title":"Burden of pneumococcal disease in adults aged 65 years and older: an Australian perspective","volume":"8","author":"Earle","year":"2016","journal-title":"Pneumonia (Nathan)."},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.066_b0165","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jiac.2017.01.008","article-title":"The distribution and annual changes in the Streptococcus pneumoniae serotypes in adult Japanese patients with pneumococcal pneumonia from 2011 to 2015","volume":"23","author":"Akata","year":"2017","journal-title":"J Infect Chemother."},{"key":"10.1016\/j.vaccine.2021.01.066_b0170","unstructured":"Albrecht P., Patrzalek M., Gorynski P. The burden of Herpes Zoster and its complications in Poland in according to the age. Przegl Epidemiol. 2015;69(4):693-7, 841\u2013843."},{"key":"10.1016\/j.vaccine.2021.01.066_b0175","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12879-015-1262-8","article-title":"Annual incidence rates of herpes zoster among an immunocompetent population in the United States","volume":"15","author":"Johnson","year":"2015","journal-title":"BMC Infect Dis."},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.066_b0180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1158\/1055-9965.EPI-15-1033","article-title":"Herpes Zoster and Risk of Cancer in the Elderly U.S Population","volume":"25","author":"Mahale","year":"2016","journal-title":"CancerEpidemiol Biomarkers Prev."},{"key":"10.1016\/j.vaccine.2021.01.066_b0185","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12879-015-1059-9","article-title":"Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France","volume":"15","author":"Blein","year":"2015","journal-title":"BMC Infect Dis."},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.066_b0190","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009689","article-title":"Is herpes zoster an additional complication in old age alongside comorbidity and multiple medications? Results of the post hoc analysis of the 12-month longitudinal prospective observational ARIZONA cohort study","volume":"6","author":"Pickering","year":"2016","journal-title":"BMJ Open."},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.066_b0195","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2471\/BLT.14.139022","article-title":"Big data in global health: improving health in low- and middle-income countries","volume":"93","author":"Wyber","year":"2015","journal-title":"Bull World Health Organ."},{"key":"10.1016\/j.vaccine.2021.01.066_b0200","unstructured":"Global Burden of Disease Study. GBD Results Tool 2017 [Available from: http:\/\/ghdx.healthdata.org\/."},{"key":"10.1016\/j.vaccine.2021.01.066_b0205","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1186\/1471-2458-14-718","article-title":"Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States","volume":"14","author":"Michaelidis","year":"2014","journal-title":"BMC Public Health."},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.066_b0210","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/jgs.14588","article-title":"Cost-effectiveness of the 4 pillars practice transformation program to improve vaccination of adults aged 65 and older","volume":"65","author":"Smith","year":"2017","journal-title":"J Am Geriatr Soc."},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.066_b0215","first-page":"e30","article-title":"Cost-effectiveness of pneumococcal and influenza vaccination standing order programs","volume":"19","author":"Lin","year":"2013","journal-title":"Am J Manag Care."},{"issue":"25","key":"10.1016\/j.vaccine.2021.01.066_b0220","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.jacc.2008.09.018","article-title":"Interpreting the results of cost-effectiveness studies","volume":"52","author":"Cohen","year":"2008","journal-title":"J Am Coll Cardiol."},{"issue":"33","key":"10.1016\/j.vaccine.2021.01.066_b0225","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1016\/j.vaccine.2014.05.015","article-title":"Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel","volume":"32","author":"Yamin","year":"2014","journal-title":"Vaccine."},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.066_b0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149540","article-title":"Cost-effectiveness of vaccinating immunocompetent >\/=65 year olds with the 13-valent pneumococcal conjugate vaccine in England","volume":"11","author":"van Hoek","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.vaccine.2021.01.066_b0235","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1186\/1471-2334-13-597","article-title":"Rationale and design of the costs, health status and outcomes in community-acquired pneumonia (CHO-CAP) study in elderly persons hospitalized with CAP","volume":"13","author":"Mangen","year":"2013","journal-title":"BMC Infect Dis."},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.066_b0240","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/21645515.2016.1256928","article-title":"Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America","volume":"13","author":"Jamotte","year":"2017","journal-title":"Hum Vaccin Immunother."},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.066_b0245","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1586\/erp.13.19","article-title":"Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis","volume":"13","author":"Bresse","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.066_b0250","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4161\/hv.26886","article-title":"Medical and economic burden of influenza in the elderly population in central and eastern European countries","volume":"10","author":"Kovacs","year":"2014","journal-title":"Hum Vaccin Immunother."},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.066_b0255","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.vaccine.2014.10.079","article-title":"Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors","volume":"33","author":"Chit","year":"2015","journal-title":"Vaccine."},{"issue":"7","key":"10.1016\/j.vaccine.2021.01.066_b0260","first-page":"872","article-title":"Budget-impact analysis of alternative herpes zoster vaccine strategies: a U.S","volume":"22","author":"Graham","year":"2016","journal-title":"HMO Perspective. J Manag Care Spec Pharm."},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.066_b0265","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4161\/hv.26888","article-title":"Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy: an economic evaluation","volume":"10","author":"Liguori","year":"2014","journal-title":"Hum Vaccin Immunother."},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.066_b0270","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jep.12131","article-title":"Economic impact of 13-valent pneumococcal conjugate vaccine in Finnish adults >\/=50 years with underlying chronic medical conditions","volume":"20","author":"Martikainen","year":"2014","journal-title":"J Eval Clin Pract."},{"key":"10.1016\/j.vaccine.2021.01.066_b0275","article-title":"Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model","author":"Pradas","year":"201313175","journal-title":"BMC Infect Dis."},{"issue":"7","key":"10.1016\/j.vaccine.2021.01.066_b0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132922","article-title":"Net costs due to seasonal influenza vaccination-United States, 2005\u20132009","volume":"10","author":"Carias","year":"2015","journal-title":"PLoS One."},{"issue":"12","key":"10.1016\/j.vaccine.2021.01.066_b0285","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.vaccine.2014.01.017","article-title":"The cost-effectiveness of influenza vaccination in elderly Australians: an exploratory analysis of the vaccine efficacy required","volume":"32","author":"Newall","year":"2014","journal-title":"Vaccine."},{"issue":"37","key":"10.1016\/j.vaccine.2021.01.066_b0290","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1016\/j.vaccine.2013.06.037","article-title":"Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults","volume":"31","author":"Smith","year":"2013","journal-title":"Vaccine."},{"issue":"18","key":"10.1016\/j.vaccine.2021.01.066_b0295","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.vaccine.2016.03.003","article-title":"The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: An exploration of influential factors for Belgium","volume":"34","author":"Blommaert","year":"2016","journal-title":"Vaccine."},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.066_b0300","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40261-015-0345-z","article-title":"Cost effectiveness of the 13-valent pneumococcal conjugate vaccination program in chronic obstructive pulmonary disease patients aged 50+ years in Spain","volume":"36","author":"Rodriguez Gonzalez-Moro","year":"2016","journal-title":"Clin Drug Investig."},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.066_b0305","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amepre.2012.11.035","article-title":"Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults","volume":"44","author":"Smith","year":"2013","journal-title":"Am J Prev Med."},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.066_b0310","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4161\/hv.23268","article-title":"Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy","volume":"9","author":"Boccalini","year":"2013","journal-title":"Hum Vaccin Immunother."},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.066_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130217","article-title":"Cost-effectiveness analysis of universal vaccination of adults aged 60 Years with 23-valent pneumococcal polysaccharide vaccine versus current practice in Brazil","volume":"10","author":"de Soarez","year":"2015","journal-title":"PLoS One."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2021.01.066_b0320","doi-asserted-by":"crossref","first-page":"A29","DOI":"10.1016\/j.vaccine.2016.12.001","article-title":"Moving beyond traditional valuation of vaccination: needs and opportunities","volume":"35","author":"Bloom","year":"2017","journal-title":"Vaccine."},{"issue":"45","key":"10.1016\/j.vaccine.2021.01.066_b0325","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1016\/j.vaccine.2016.07.045","article-title":"A global review of national influenza immunization policies: analysis of the 2014 WHO\/UNICEF joint reporting form on immunization","volume":"34","author":"Ortiz","year":"2016","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.01.066_b0330","unstructured":"Public Health England. Shingles: guidance and vaccination programme 2017 [Available from: https:\/\/www.gov.uk\/government\/collections\/shingles-vaccination-programme."},{"key":"10.1016\/j.vaccine.2021.01.066_b0335","doi-asserted-by":"crossref","DOI":"10.1186\/1744-8603-1-6","article-title":"Global health priorities \u2013 priorities of the wealthy?","author":"Ollila","year":"2005","journal-title":"Globalization and Health"},{"key":"10.1016\/j.vaccine.2021.01.066_b0340","series-title":"Oxford University Press","article-title":"Understanding contemporary aid relationships","author":"Fraser","year":"2009"},{"issue":"9681","key":"10.1016\/j.vaccine.2021.01.066_b0345","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(09)60881-3","article-title":"Financing of global health: tracking development assistance for health from 1990 to 2007","volume":"373","author":"Ravishankar","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.01.066_b0350","unstructured":"World Health Organization. WHO recommends seasonal influenza vaccination to pregnant women as the highest priority. 2012."},{"issue":"9","key":"10.1016\/j.vaccine.2021.01.066_b0355","first-page":"2180","article-title":"Adult immunization in India: Importance and recommendations","volume":"11","author":"Verma","year":"2015","journal-title":"Hum Vaccin Immunother."},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.066_b0360","first-page":"345","article-title":"Financing of global health: tracking development assistance for health from 1990 to 2007","volume":"57","author":"Sharma","year":"2009","journal-title":"J Assoc Physic India."},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.066_b0365","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00038-012-0438-x","article-title":"Adult immunization policies in advanced economies: vaccination recommendations, financing, and vaccination coverage","volume":"58","author":"Wu","year":"2013","journal-title":"Int J Public Health."},{"issue":"9","key":"10.1016\/j.vaccine.2021.01.066_b0370","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.4161\/21645515.2014.982998","article-title":"Adult vaccination: Now is the time to realize an unfulfilled potential","volume":"11","author":"Tan","year":"2016","journal-title":"Hum Vaccin Immunother."},{"key":"10.1016\/j.vaccine.2021.01.066_b0375","doi-asserted-by":"crossref","unstructured":"Memish Z, Al Hakeem R, Al Neel O, Danis K, Jasir A, Eibach D. Laboratory-confirmed invasive meningococcal disease: effect of the Hajj vaccination policy, Saudi Arabia, 1995 to 2011. Euro Surveill. 2013;18(37).","DOI":"10.2807\/1560-7917.ES2013.18.37.20581"},{"key":"10.1016\/j.vaccine.2021.01.066_b0380","first-page":"e11","article-title":"Impact of the Hajj on pneumococcal transmission","author":"Memish","year":"201521177","journal-title":"Clin Microbiol Infect."},{"issue":"9934","key":"10.1016\/j.vaccine.2021.01.066_b0385","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(14)60381-0","article-title":"Hajj: infectious disease surveillance and control","volume":"383","author":"Memish","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.066_b0390","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.tmaid.2013.06.001","article-title":"The potential for pneumococcal vaccination in Hajj pilgrims: expert opinion","volume":"11","author":"Rashid","year":"2013","journal-title":"Travel Med Infect Dis."},{"key":"10.1016\/j.vaccine.2021.01.066_b0395","unstructured":"U.S. Centers for Disease Control and Prevention. Saudi Arabia: Hajj\/Umrah Pilgrimage. CDC Yellow Book 2020: Health Information for International Travel. New York: Oxford University Press; 2020."},{"key":"10.1016\/j.vaccine.2021.01.066_b0400","unstructured":"Ministry of Health. General Guide for Health of Hajj and Umrah Pilgrims. 3rd ed, 1438H (2017G). Government of Saudi Arabia."},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.066_b0405","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1086\/662715","article-title":"Updated recommendations of the Advisory Committee on Immunization Practices for healthcare personnel vaccination: a necessary foundation for the essential work that remains to build successful programs","volume":"33","author":"Shefer","year":"2012","journal-title":"Infect Control Hosp Epidemiol."},{"key":"10.1016\/j.vaccine.2021.01.066_b0410","unstructured":"U.S. Centers for Disease Control and Prevention. Recommended Vaccines for Healthcare Workers 2016 [Available from: https:\/\/www.cdc.gov\/vaccines\/adults\/rec-vac\/hcw.html#recs."},{"key":"10.1016\/j.vaccine.2021.01.066_b0415","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fimmu.2013.00171","article-title":"Immunosenescence and novel vaccination strategies for the elderly","volume":"4","author":"Dorrington","year":"2013","journal-title":"Front Immunol."},{"key":"10.1016\/j.vaccine.2021.01.066_b0420","unstructured":"World Health Organization. Working Group on Metrics and Research Standards on Healthy Ageing - 27-31 March 2017. [Available from: http:\/\/www.who.int\/ageing\/data-research\/metrics-standards\/en\/."},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.066_b0425","doi-asserted-by":"crossref","first-page":"NP936","DOI":"10.1177\/1010539512460269","article-title":"Estimation of the direct cost of treating people aged more than 60 years infected by influenza virus in Shanghai","volume":"27","author":"Chen","year":"2015","journal-title":"Asia Pac J Public Health."},{"issue":"10","key":"10.1016\/j.vaccine.2021.01.066_b0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139140","article-title":"Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan","volume":"10","author":"Hoshi","year":"2015","journal-title":"PLoS One."},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.066_b0435","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3111\/13696998.2016.1146726","article-title":"The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older","volume":"19","author":"Lopez-Belmonte","year":"2016","journal-title":"J Med Econ."},{"issue":"7","key":"10.1016\/j.vaccine.2021.01.066_b0440","first-page":"558","article-title":"Impact of an interprofessional teaching clinic on preventive care services","volume":"47","author":"Zorek","year":"2015","journal-title":"Fam Med."},{"issue":"33","key":"10.1016\/j.vaccine.2021.01.066_b0445","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/j.vaccine.2017.06.003","article-title":"The complexity and cost of vaccine manufacturing - an overview","volume":"35","author":"Plotkin","year":"2017","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.01.066_b0450","doi-asserted-by":"crossref","unstructured":"Pagliusi S, Ting CC, Lobos F, Group DEC. Vaccines: Shaping global health. Vaccine. 2017;35(12):1579-85.","DOI":"10.1016\/j.vaccine.2017.02.017"},{"key":"10.1016\/j.vaccine.2021.01.066_b0455","doi-asserted-by":"crossref","first-page":"100066","DOI":"10.1016\/j.jvacx.2020.100066","article-title":"Emerging vaccine manufacturers are innovating for the next decade","volume":"5","author":"Hayman","year":"2020","journal-title":"Vaccine X."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:53:20Z","timestamp":1759402400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21001079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":91,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0264410X21001079"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.066","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}